메뉴 건너뛰기




Volumn 25, Issue 7, 2011, Pages

ALK-targeted therapy for lung cancer: Ready for prime time

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; ONCOPROTEIN; PEMETREXED; RETASPIMYCIN; UNCLASSIFIED DRUG;

EID: 79960217035     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (10)

References (19)
  • 1
    • 12144258439 scopus 로고    scopus 로고
    • The emerging normal and disease-related roles of anaplastic lymphoma kinase
    • Pulford K, Lamant L, Espinos E, et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci. 2004;61:2939-53.
    • (2004) Cell Mol Life Sci , vol.61 , pp. 2939-2953
    • Pulford, K.1    Lamant, L.2    Espinos, E.3
  • 2
    • 0036731704 scopus 로고    scopus 로고
    • Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma
    • Kutok JL, Aster JC. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J ClinOncol. 2002;20:3691-702.
    • (2002) J ClinOncol , vol.20 , pp. 3691-3702
    • Kutok, J.L.1    Aster, J.C.2
  • 3
    • 54049120220 scopus 로고    scopus 로고
    • Activating mutations in ALK provide atherapeutic target in neuroblastoma
    • George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide atherapeutic target in neuroblastoma. Nature. 2008;455:975-8.
    • (2008) Nature , vol.455 , pp. 975-978
    • George, R.E.1    Sanda, T.2    Hanna, M.3
  • 4
    • 54049094708 scopus 로고    scopus 로고
    • Identification of ALK as a major familial neuroblastoma predisposition gene
    • Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930-5.
    • (2008) Nature , vol.455 , pp. 930-935
    • Mossé, Y.P.1    Laudenslager, M.2    Longo, L.3
  • 5
    • 0028198206 scopus 로고
    • Fusion of a kinase gene, ALK, to a nucleolar protein gene NPM, in non-Hodgkins lymphoma
    • Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene NPM, in non-Hodgkins lymphoma. Science. 1994; 263:1281-4.
    • (1994) Science , vol.263 , pp. 1281-1284
    • Morris, S.W.1    Kirstein, M.N.2    Valentine, M.B.3
  • 6
    • 0031008896 scopus 로고    scopus 로고
    • ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkins lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
    • Morris SW, Naeve C, Matthew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkins lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 1997;14:2175-88.
    • (1997) Oncogene , vol.14 , pp. 2175-2188
    • Morris, S.W.1    Naeve, C.2    Matthew, P.3
  • 7
    • 34547638047 scopus 로고    scopus 로고
    • Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer
    • Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature. 2007;448:561-6.
    • (2007) Nature , vol.448 , pp. 561-566
    • Soda, M.1    Choi, Y.L.2    Enomoto, M.3
  • 8
    • 34948834758 scopus 로고    scopus 로고
    • Pathobiology of ALK+ anaplastic large cell lymphoma
    • Amin HM, Lai R. Pathobiology of ALK+ anaplastic large cell lymphoma. Blood. 2007;110:2259-67.
    • (2007) Blood , vol.110 , pp. 2259-2267
    • Amin, H.M.1    Lai, R.2
  • 9
    • 48549098388 scopus 로고    scopus 로고
    • Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer
    • Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008;68:4971-6.
    • (2008) Cancer Res , vol.68 , pp. 4971-4976
    • Choi, Y.L.1    Takeuchi, K.2    Soda, M.3
  • 10
    • 78650950138 scopus 로고    scopus 로고
    • EGFR and EML4-ALK mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations
    • Tiseo M, Gelsomino F, Boggiani D, et al. EGFR and EML4-ALK mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer. 2011;71:241-3.
    • (2011) Lung Cancer , vol.71 , pp. 241-243
    • Tiseo, M.1    Gelsomino, F.2    Boggiani, D.3
  • 11
    • 70349336416 scopus 로고    scopus 로고
    • Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK
    • Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247-53.
    • (2009) J Clin Oncol , vol.27 , pp. 4247-4253
    • Shaw, A.T.1    Yeap, B.Y.2    Mino-Kenudson, M.3
  • 12
    • 69349083935 scopus 로고    scopus 로고
    • Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the Western populations
    • Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the Western populations. Clin Cancer Res. 2009;15:5216-23.
    • (2009) Clin Cancer Res , vol.15 , pp. 5216-5223
    • Rodig, S.J.1    Mino-Kenudson, M.2    Dacic, S.3
  • 13
    • 77649091118 scopus 로고    scopus 로고
    • A novel highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry
    • Mino-Kenudson M, Chirieac LR, Law K, et al. A novel highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16:1561-71.
    • (2010) Clin Cancer Res , vol.16 , pp. 1561-1571
    • Mino-Kenudson, M.1    Chirieac, L.R.2    Law, K.3
  • 14
    • 37549059613 scopus 로고    scopus 로고
    • Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large cell lymphoma
    • Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large cell lymphoma. Mol Cancer Ther. 2007;3314-22.
    • (2007) Mol Cancer Ther , pp. 3314-3322
    • Christensen, J.G.1    Zou, H.Y.2    Arango, M.E.3
  • 15
    • 78049425319 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase inhibition in non-small cell lung cancer
    • Kwak EL, Bang Y-J, Camidge R, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med. 2010;363:1693-1703.
    • (2010) N Engl J Med , vol.363 , pp. 1693-1703
    • Kwak, E.L.1    Bang, Y.-J.2    Camidge, R.3
  • 16
    • 64649091718 scopus 로고    scopus 로고
    • Meta-analysis of single agent chemotherapy compared with combination chemotherapy as second line treatment for advanced non-small cell lung cancer
    • Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single agent chemotherapy compared with combination chemotherapy as second line treatment for advanced non-small cell lung cancer. J Clin Oncol. 2009;27:1836-43.
    • (2009) J Clin Oncol , vol.27 , pp. 1836-1843
    • di Maio, M.1    Chiodini, P.2    Georgoulias, V.3
  • 17
    • 78049426513 scopus 로고    scopus 로고
    • EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
    • Choi YL, Soda M, Tanio Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363:1734-9.
    • (2010) N Engl J Med , vol.363 , pp. 1734-1739
    • Choi, Y.L.1    Soda, M.2    Tanio, Y.3
  • 18
    • 79960250811 scopus 로고    scopus 로고
    • Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors
    • May 25 [Epub ahead of print]
    • Lovly CM, Heuckmann JM, de Stanchina E, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 2011; May 25 [Epub ahead of print]
    • (2011) Cancer Res
    • Lovly, C.M.1    Heuckmann, J.M.2    de Stanchina, E.3
  • 19
    • 79957896979 scopus 로고    scopus 로고
    • The HSP90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models
    • Jan 24 [Epub ahead of print]
    • Normant E, Paez G, West KA, et al. The HSP90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene. 2011;Jan 24 [Epub ahead of print]
    • (2011) Oncogene
    • Normant, E.1    Paez, G.2    West, K.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.